Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Human Papillomavirus 9-valent Vaccine · 1 trial · 2 indications
Antibody titers against meningococcal serogroups A, C, W, and Y were measured by serum bactericidal assay using human complement (hSBA). Non-inferiority data analysis for this outcome measure was planned to be conducted only for Groups 1 and 2, not for Group 3. Group 3 data is reported separately.
| Arm | Type | Description |
|---|---|---|
| Group 1: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Sequential Administration) | EXPERIMENTAL | Participants received 0.5-milliliter (mL) intramuscular injection of MenACYW Conjugate vaccine on Day 01 and 0.5-mL intramuscular injection of 9vHPV + Tdap-IPV vaccines (sequentially after MenACYW vaccine) at Day 31. |
| Group 2: Nimenrix® + 9vHPV + Tdap-IPV Vaccines (Sequential Administration) | ACTIVE_COMPARATOR | Participants received 0.5-mL intramuscular injection of Nimenrix® vaccine on Day 01 and 0.5-mL intramuscular injection of 9vHPV + Tdap-IPV vaccines (sequentially after Nimenrix® vaccine) at Day 31. |
| Group 3: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Concomitant Administration) | EXPERIMENTAL | Participants received 0.5-mL intramuscular injection of MenACYW Conjugate vaccine concomitantly with 9vHPV + Tdap-IPV vaccines on Day 01. |
| Name | Type | Description |
|---|---|---|
| Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine) | BIOLOGICAL | Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular |
| Meningococcal group A, C, W-135, and Y conjugate vaccine | BIOLOGICAL | Pharmaceutical form: Powder and solvent for solution for injection Route of administration: Intramuscular |
| Human Papillomavirus 9-valent Vaccine (9vHPV) | BIOLOGICAL | Pharmaceutical form: Suspension for injection Route of administration: Intramuscular |
| Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV) | BIOLOGICAL | Pharmaceutical form: Suspension for injection Route of administration: Intramuscular |
Inclusion Criteria: * Aged 10 to 17 years on the day of inclusion ('10 to 17 years' means from the day of the 10th birthday to the day before the 18th birthday). * Meningococcal serogroup C Conjugate vaccine (MenC) naïve participants or participants having received monovalent MenC priming in infanc...
Human Papillomavirus 9-valent Vaccine is being studied for meningococcal immunisation in healthy adolescents. It is an investigational monoclonal antibody in Phase 3 clinical development, evaluated for its ability to provide protection against meningococcal disease.
Sanofi (ticker: SNY) is developing Human Papillomavirus 9-valent Vaccine. The company is conducting clinical trials to evaluate the vaccine's safety and efficacy for meningococcal immunisation in adolescent populations.
Human Papillomavirus 9-valent Vaccine is in Phase 3 clinical development. It is an investigational product, not yet approved, and is being studied for meningococcal immunisation in healthy adolescents.
Human Papillomavirus 9-valent Vaccine is associated with clinical trial NCT04490018, a Phase 3 study comparing a quadrivalent meningococcal conjugate vaccine to a reference vaccine in healthy adolescents. The trial enrolled 463 participants across Hungary, Italy, Singapore, and Spain.
Human Papillomavirus 9-valent Vaccine is a monoclonal antibody designed to target meningococcal bacteria. It is being evaluated for its ability to stimulate an immune response that provides protection against meningococcal disease in healthy adolescents.